Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

tes; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any further product success; and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2012.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise, unless required by law.

This news release and/or the financial results attached to this news release include amounts that are considered "non-GAAP financial measures" under SEC rules.  As required, Regeneron has provided reconciliations of these measures.Contacts Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.847.7799

914.847.764michael.aberman@regeneron.com

peter.dworkin@regeneron.com TABLE 1REGENERON PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(In thousands)March 31,December 31,20132012ASSETSCash, restricted cash, and marketable securities$

662,811$

587,511Accounts receivable - trade, net703,857593,207Accounts
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
(Date:7/24/2014)... 2014 Research and Markets has ... Proteomics Analytical Instruments Market 2014-2018" report to their ... Genomics is the study of the gene and ... structure and functions of proteomes or sets of proteins ... Genomics involves the mapping of genes and DNA sequencing ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... 14 CJPS Enterprises, LLC, the,operator of the ... put online more resources for Michigan companies looking ... grow their existing healthcare,business. Those resources can be ... is dedicated to providing users with information regarding,the ...
... China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... ,the Company,) (Amex: CSY ), a,leading ... drugs in the People,s Republic of China ... nasal spray for the treatment,and prevention of ...
... the Industry,s Largest eClinical Technology ... ... 14 PAREXEL International,Corporation (Nasdaq: PRXL ), a leading ... acquisition of,ClinPhone plc, a leading clinical technology organization. By combining,ClinPhone ...
Cached Biology Technology:The Michigan Life Sciences Pipeline Adds More Resources On Its Website 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 3PAREXEL Closes the Acquisition of ClinPhone 2PAREXEL Closes the Acquisition of ClinPhone 3PAREXEL Closes the Acquisition of ClinPhone 4PAREXEL Closes the Acquisition of ClinPhone 5
(Date:7/25/2014)... 25 countries and 35 states will attend the ... Society of America (GSA) next week at the ... feature close to 500 presentations (including 70 talks) ... expression and regulation, functional genomics, chemical biology and ... variety of diseases. , Of special note ...
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... A majority of women with breast cancer today are candidates ... tissue. Results of a UC Davis study, however, show that ... breast are treated with a second lumpectomy rather than a ... years those women survive in half. "We were ...
... living in communities often rely on friends to help get ... of Cameron Currie at the University of Wisconsin-Madison, many microbes, ... Currie team,s study, which was funded by the National Science ... of the journal Science , describes the complex relationship ...
... Dunn Research Foundation has awarded a $3 million grant ... biomedical science that have the potential for clinical applications. ... researchers whose studies will be conducted at the Collaborative ... corner of University Boulevard and Main Street. To qualify ...
Cached Biology News:Second lumpectomy for breast cancer reduces survival rates 2Beetles get by with a little help from their friends 2
... is a unique alternative to traditional ... acetate-EDTA) electrophoresis buffers. Bionic Buffer allows ... running times, and high-resolution band separation. ... electrophoresis after dilution to working 1x ...
... fast and easy method for the ... from mammalian tissues. Most of the ... outer membranes. The kit contains extraction ... proteome profiling. Also included is a ...
The Mu-End™ Protein Truncation Kit provides a convenient method for generating a library of N-terminal and C-terminal protein deletions that can be expressed in E. coli....
Sufficient reagents for 50 applications.Mitochondria Isolation Kit Reagent A, 50 ml Mitochondria Isolation Kit Reagent B, 500 l Mitochondria Isolation Kit Reagent C, 70 ml...
Biology Products: